Eton Pharmaceuticals, Inc. Shareholders' Equity
Eton Pharmaceuticals, Inc. (ETON) had Shareholders' Equity of $46.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $46.59M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $30.61M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $26.15M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $23.13M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $46.59M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $30.61M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $26.15M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $23.13M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $23.96M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $24.45M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $24.43M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $15.98M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $13.46M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $15.49M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $15.48M 10-K · filed 2026-03-19 | |
| 2023-09-30 | $16.89M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $16.73M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $11.24M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $13.08M 10-K · filed 2026-03-19 | |
| 2022-09-30 | $11.18M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $13.24M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $13.38M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $17.63M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $15.66M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $20.74M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $21.55M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $17.63M 10-K · filed 2025-03-18 | $15.66M 10-K · filed 2021-03-16 |
| 2020-09-30 | $1.39M 10-Q · filed 2021-11-16 | |
| 2020-06-30 | $7.03M 10-Q · filed 2021-11-16 | |
| 2020-03-31 | $10.62M 10-Q · filed 2021-08-16 | |
| 2019-12-31 | $10.55M 10-K · filed 2023-03-16 | |
| 2019-09-30 | $12.35M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $16.70M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $19.24M 10-Q · filed 2020-08-12 | |
| 2018-12-31 | $26.30M 10-K · filed 2022-03-16 | |
| 2018-09-30 | -$16.41M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$12.94M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | -$9.55M 10-Q · filed 2019-08-06 | |
| 2017-12-31 | -$6.87M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |